Corrigendum to: “Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment” [Exp. Cell. Res. 2014 15 323(1) 155–64](S0014482714000834)(10.1016/j.yexcr.2014.02.020));Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment

Experimental Cell Research

Volumn 323, Issue 1, 2014, Pages 155-164

  Kim, Jong Hyuk ^a,b   Frantz, Aric M ^a   Anderson, Katie L ^a   Graef, Ashley J ^a   Scott, Milcah C ^a   Robinson, Sally ^a   Sharkey, Leslie C ^a,b   O'Brien, Timothy D ^a   Dickerson, Erin B ^a,b   Modiano, Jaime F ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Canine; Gene expression profiling; Hemangiosarcoma; Interleukin 8; Tumor microenvironment

Indexed keywords

CALCIUM ION; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CANCER GROWTH; CANCER MORPHOLOGY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOG DISEASE; GENE EXPRESSION PROFILING; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEADY STATE; TUMOR ENGRAFTMENT; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION;

CANINE; GENE EXPRESSION PROFILING; HEMANGIOSARCOMA; INTERLEUKIN-8; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, NEUTRALIZING; CALCIUM; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOGS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOSARCOMA; INTERLEUKIN-8; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-8; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84896449673     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2018.07.012     Document Type: Erratum

References (39)

1. Goldschmidt M.H., Hendrick M.J. Skin and soft tissue. Tumours in Domestic Animals 2002, 45-117. Iowa State Press, Ames. D.J. Meuten (Ed.).
2. Goritz M., Muller K., Krastel D., Staudacher G., Schmidt P., Kuhn M., Nickel R., Schoon H.A. Canine splenic haemangiosarcoma: influence of metastases, chemotherapy and growth pattern on post-splenectomy survival and expression of angiogenic factors. J. Comp. Pathol. 2012.
3. Lamerato-Kozicki A.R., Helm K.M., Jubala C.M., Cutter G.C., Modiano J.F. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp. Hematol. 2006, 34:870-878.
4. Clifford C.A., Mackin A.J., Henry C.J. Treatment of canine hemangiosarcoma: 2000 and beyond. J. Vet. Intern. Med. 2000, 14:479-485.
5. Lana S., U[U+05F3]Ren L., Plaza S., Elmslie R., Gustafson D., Morley P., Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J. Vet. Intern. Med. 2007, 21:764-769.
6. U[U+05F3]Ren L.W., Biller B.J., Elmslie R.E., Thamm D.H., Dow S.W. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J. Vet. Intern. Med. 2007, 21:113-120.
7. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
8. Tobler A., Moser B., Dewald B., Geiser T., Studer H., Baggiolini M., Fey M.F. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 1993, 82:2517-2525.
9. Cheng G.Z., Park S., Shu S., He L., Kong W., Zhang W., Yuan Z., Wang L.H., Cheng J.Q. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 2008, 8:2-6.
10. MacManus C.F., Pettigrew J., Seaton A., Wilson C., Maxwell P.J., Berlingeri S., Purcell C., McGurk M., Johnston P.G., Waugh D.J. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol. Cancer Res. 2007, 5:737-748.
11. Venkatakrishnan G., Salgia R., Groopman J.E. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J. Biol. Chem. 2000, 275:6868-6875.
12. Yao C., Lin Y., Chua M.S., Ye C.S., Bi J., Li W., Zhu Y.F., Wang S.M. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int. J. Cancer 2007, 121:1949-1957.
13. Lang K., Niggemann B., Zanker K.S., Entschladen F. Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int. J. Cancer 2002, 99:673-680.
14. De Larco J.E., Wuertz B.R., Furcht L.T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin. Cancer Res. 2004, 10:4895-4900.
15. Yuan A., Chen J.J., Yao P.L., Yang P.C. The role of interleukin-8 in cancer cells and microenvironment interaction. Front. Biosci. 2005, 10:853-865.
16. Lee Y.S., Choi I., Ning Y., Kim N.Y., Khatchadourian V., Yang D., Chung H.K., Choi D., LaBonte M.J., Ladner R.D., Nagulapalli Venkata K.C., Rosenberg D.O., Petasis N.A., Lenz H.J., Hong Y.K. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br. J. Cancer 2012, 106:1833-1841.
17. Tamburini B.A., Phang T.L., Fosmire S.P., Scott M.C., Trapp S.C., Duckett M.M., Robinson S.R., Slansky J.E., Sharkey L.C., Cutter G.R., Wojcieszyn J.W., Bellgrau D., Gemmill R.M., Hunter L.E., Modiano J.F. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer 2010, 10:619.
18. Gelaleti G.B., Jardim B.V., Leonel C., Moschetta M.G., Zuccari D.A. Interleukin-8 as a prognostic serum marker in canine mammary gland neoplasias. Vet. Immunol. Immunopathol. 2012, 146:106-112.
19. de Andres P.J., Illera J.C., Caceres S., Diez L., Perez-Alenza M.D., Pena L. Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer. Vet. Immunol. Immunopathol. 2013, 152:245-251.
20. Fosmire S.P., Dickerson E.B., Scott A.M., Bianco S.R., Pettengill M.J., Meylemans H., Padilla M., Frazer-Abel A.A., Akhtar N., Getzy D.M., Wojcieszyn J., Breen M., Helfand S.C., Modiano J.F. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab. Invest. 2004, 84:562-572.
21. Modiano J.F., Bellgrau D., Cutter G.R., Lana S.E., Ehrhart N.P., Ehrhart E., Wilke V.L., Charles J.B., Munson S., Scott M.C., Pozniak J., Carlson C.S., Schaack J., Duke R.C. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol. Ther. 2012, 20:2234-2243.
22. Tamburini B.A., Trapp S., Phang T.L., Schappa J.T., Hunter L.E., Modiano J.F. Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One 2009, 4:e5549.
23. Scott M.C., Sarver A.L., Gavin K.J., Thayanithy V., Getzy D.M., Newman R.A., Cutter G.R., Lindblad-Toh K., Kisseberth W.C., Hunter L.E., Subramanian S., Breen M., Modiano J.F. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 2011, 49:356-367.
24. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
25. Akhtar N., Padilla M.L., Dickerson E.B., Steinberg H., Breen M., Auerbach R., Helfand S.C. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004, 6:106-116.
26. Modiano J.F., Ritt M.G., Wojcieszyn J., Smith R. Growth arrest of melanoma cells is differentially regulated by contact inhibition and serum deprivation. DNA Cell Biol. 1999, 18:357-367.
27. Ritt M.G., Mayor J., Wojcieszyn J., Smith R., Barton C.L., Modiano J.F. Sustained nuclear localization of p21/WAF-1 upon growth arrest induced by contact inhibition. Cancer Lett. 2000, 158:73-84.
28. Gangadharan C., Thoh M., Manna S.K. Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL. Breast Cancer Res. Treat. 2010, 120:671-683.
29. Asfaha S., Dubeykovskiy A.N., Tomita H., Yang X., Stokes S., Shibata W., Friedman R.A., Ariyama H., Dubeykovskaya Z.A., Muthupalani S., Ericksen R., Frucht H., Fox J.G., Wang T.C. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 2013, 144:155-166.
30. Medina R.J., O[U+05F3]Neill C.L., O[U+05F3]Doherty T.M., Knott H., Guduric-Fuchs J., Gardiner T.A., Stitt A.W. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol. Med. 2011, 17:1045-1055.
31. Gu F.M., Li Q.L., Gao Q., Jiang J.H., Zhu K., Huang X.Y., Pan J.F., Yan J., Hu J.H., Wang Z., Dai Z., Fan J., Zhou J. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol. Cancer 2011, 10:150.
32. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 2009, 361:888-898.
33. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., Huang E., Finlayson E., Simeone D., Welling T.H., Chang A., Coukos G., Liu R., Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
34. Mian B.M., Dinney C.P., Bermejo C.E., Sweeney P., Tellez C., Yang X.D., Gudas J.M., McConkey D.J., Bar-Eli M. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin. Cancer Res. 2003, 9:3167-3175.
35. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., Gudas J.M., Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 2002, 161:125-134.
36. Holden C.A., Spittle M.F., Jones E.W. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 1987, 59:1046-1057.
37. Morrison W.H., Byers R.M., Garden A.S., Evans H.L., Ang K.K., Peters L.J. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer 1995, 76:319-327.
38. Fishman A.P. Endothelium: a distributed organ of diverse capabilities. Ann. N.Y. Acad. Sci. 1982, 401:1-8.
39. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., Pober J.S., Wick T.M., Konkle B.A., Schwartz B.S., Barnathan E.S., McCrae K.R., Hug B.A., Schmidt A.M., Stern D.M. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.